Onconova Therapeutics (ONTX) & Myovant Sciences (NYSE:MYOV) Critical Review

Onconova Therapeutics (NASDAQ: ONTX) and Myovant Sciences (NYSE:MYOV) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.

Analyst Recommendations

This is a breakdown of recent recommendations for Onconova Therapeutics and Myovant Sciences, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Onconova Therapeutics 0 0 4 0 3.00
Myovant Sciences 0 0 4 0 3.00

Onconova Therapeutics presently has a consensus target price of $7.33, indicating a potential upside of 305.16%. Myovant Sciences has a consensus target price of $22.50, indicating a potential upside of 57.89%. Given Onconova Therapeutics’ higher probable upside, equities research analysts clearly believe Onconova Therapeutics is more favorable than Myovant Sciences.


This table compares Onconova Therapeutics and Myovant Sciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Onconova Therapeutics -2,855.94% -558.97% -144.30%
Myovant Sciences N/A -53.75% -48.90%

Valuation and Earnings

This table compares Onconova Therapeutics and Myovant Sciences’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Onconova Therapeutics $5.55 million 3.51 -$19.66 million ($3.03) -0.60
Myovant Sciences N/A N/A -$83.44 million ($1.41) -10.11

Onconova Therapeutics has higher revenue and earnings than Myovant Sciences. Myovant Sciences is trading at a lower price-to-earnings ratio than Onconova Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

25.4% of Onconova Therapeutics shares are owned by institutional investors. Comparatively, 79.2% of Myovant Sciences shares are owned by institutional investors. 29.1% of Onconova Therapeutics shares are owned by company insiders. Comparatively, 2.8% of Myovant Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Onconova Therapeutics Company Profile

Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells. It has over three clinical-stage product candidates and various preclinical programs that target kinases, cellular metabolism or cell division in preclinical development. The Company’s lead product candidate, rigosertib, is being tested in both intravenous (IV) and oral formulations as a single agent, and the oral formulation is also being tested in combination with azacitidine, in clinical trials for patients with myelodysplastic syndromes (MDS), and related cancers. Its other product candidates include Briciclib and Recilisib.

Myovant Sciences Company Profile

Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. Its main product candidate is Relugolix. Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland. Inhibition of GnRH receptors decreases the release of the gonadotropins, luteinizing hormone, or LH, and follicle-stimulating hormone, or FSH, thereby decreasing the down-stream production of estrogen and progesterone by the ovaries in women and testosterone by the testes in men. It is advancing relugolix for the treatment of heavy menstrual bleeding associated with uterine fibroids, endometriosis-associated pain and prostate cancer. It intends to develop its second product candidate, RVT-602, for the treatment of female infertility as part of assisted reproduction.

Receive News & Ratings for Onconova Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Onconova Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply